Silvant Capital Management LLC Boosts Stock Position in Insulet Corporation $PODD

Silvant Capital Management LLC raised its holdings in Insulet Corporation (NASDAQ:PODD) by 17.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,935 shares of the medical instruments supplier’s stock after purchasing an additional 2,186 shares during the quarter. Silvant Capital Management LLC’s holdings in Insulet were worth $4,611,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. True Wealth Design LLC boosted its holdings in Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 72 shares during the period. Whittier Trust Co. of Nevada Inc. increased its holdings in shares of Insulet by 48.9% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 131 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 43 shares during the last quarter. Quent Capital LLC bought a new position in Insulet in the third quarter valued at $49,000. Osterweis Capital Management Inc. bought a new stake in Insulet in the 2nd quarter worth approximately $51,000. Finally, Zions Bancorporation National Association UT boosted its stake in shares of Insulet by 57.3% in the 3rd quarter. Zions Bancorporation National Association UT now owns 173 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 63 shares in the last quarter.

Insulet Stock Down 0.9%

PODD stock opened at $238.24 on Wednesday. Insulet Corporation has a fifty-two week low of $233.29 and a fifty-two week high of $354.88. The company has a market capitalization of $16.77 billion, a price-to-earnings ratio of 68.07, a price-to-earnings-growth ratio of 1.43 and a beta of 1.42. The business’s 50 day moving average price is $261.60 and its two-hundred day moving average price is $298.92. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81.

Insulet (NASDAQ:PODD) last released its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. The company had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The firm’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.15 EPS. As a group, analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on PODD. The Goldman Sachs Group reduced their price target on Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Oppenheimer cut their target price on Insulet from $365.00 to $300.00 and set an “outperform” rating on the stock in a research note on Thursday, February 19th. Canaccord Genuity Group lowered their price target on Insulet from $450.00 to $435.00 and set a “buy” rating for the company in a research report on Wednesday, February 18th. Stifel Nicolaus cut their price objective on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Finally, Truist Financial decreased their target price on Insulet from $390.00 to $360.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Twenty equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $354.57.

Insider Buying and Selling

In other Insulet news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were purchased at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the acquisition, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This represents a 13.14% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.39% of the company’s stock.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.